News & Updates

Acupuncture for 8 weeks succeeds in lowering methadone dose and reducing cravings for opioid when compared with sham acupuncture, reports a study.

Older patients with cirrhosis who are taking bisphosphonates appear to have a reduced incidence of fractures overall, according to a study.

Once-weekly treatment with HRS9531, a novel dual GLP-1* and GIP** receptor agonist, resulted in substantial reductions in body weight among Chinese patients with obesity, according to a study presented at ADA 2024.

New drug applications approved by US FDA as of 1-15 July 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Use of glucagon-like peptide-1 receptor agonist (GLP-1RA) appears to reduce the risk of inflammatory bowel disease (IBD)-related surgery in patients with type 2 diabetes mellitus (T2DM) and concomitant ulcerative colitis (UC) or Crohn’s disease (CD), according to a retrospective study.